Received Sep 23, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 1 | — | — |
Covid infection; Covid infection; horrible skin melanoma; horrible skin melanoma; This is a spontaneous report received from a Consumer or other non HCP. An adult female patient (not pregnant) received BNT162b2 omicron (lp.8.1) (COMIRNATY (2025-2026 FORMULA)), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Melanoma" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: MALIGNANT MELANOMA (medically significant, life threatening), RECURRENT CANCER (medically significant, life threatening) all with onset 17Sep2025 at 19:15, outcome "unknown" and all described as "horrible skin melanoma"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Covid infection". Clinical course: One of the reporter's students got horrible skin melanoma after taking the Pfizer vaccine. The doctors initially suspected it might have developed following her Covid infection, but now they suspect it might be related to the Covid vaccine itself. It was reported that skin melanoma resulted in life threatening illness (immediate risk of death from the event). It was unknown if therapeutic measures were taken as a result of malignant melanoma, recurrent cancer. The information on the batch/lot number for BNT162b2 omicron (lp.8.1) will be requested and submitted if and when received.
Medical History/Concurrent Conditions: Melanoma